<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906565</url>
  </required_header>
  <id_info>
    <org_study_id>BG01-1811</org_study_id>
    <nct_id>NCT03906565</nct_id>
  </id_info>
  <brief_title>Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer After Failure or Intolerability to Second-line Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Biostar Technologies, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Biostar Pharmaceuticals, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Biostar Technologies, Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness and safety of utidelone injection in patients with advanced or&#xD;
      metastatic colorectal cancer (CRC) as a phase II trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response to utidelone treatment</measure>
    <time_frame>6 months from first study treatment</time_frame>
    <description>Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR）ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year from first study treatment</time_frame>
    <description>PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 year from first study treatment</time_frame>
    <description>OS is defined as the duration of time from first study treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile associated with utidelone injection</measure>
    <time_frame>1 year from first study treatment</time_frame>
    <description>Observe and record adverse effects and severe adverse effects associated with utidelone injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced or Metastatic CRC</condition>
  <arm_group>
    <arm_group_label>utidelone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>utidelone injection</intervention_name>
    <description>utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection</description>
    <arm_group_label>utidelone</arm_group_label>
    <other_name>UTD1 injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed informed consent form; good compliance during the whole study;&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of unresectable advanced or&#xD;
             metastatic CRC, not including appendix and anal canal cancer;&#xD;
&#xD;
          3. patients failed or intolerable to previous standard second-line treatment for locally&#xD;
             advanced or metastatic CRC;&#xD;
&#xD;
          4. Patients who have not received previous bevacizumab therapy can be treated in&#xD;
             combination with bevacizumab;&#xD;
&#xD;
          5. Patients who did not receive chemotherapy, radiotherapy, surgical therapy, molecularly&#xD;
             targeted drug therapy 4 weeks prior to enrollment, with no plan for concurrent other&#xD;
             chemotherapy and surgery;&#xD;
&#xD;
          6. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy≥ 3 months;&#xD;
&#xD;
          7. Patients must have at least one measurable target lesion with long axis ≥10 mm on CT&#xD;
             or MRI, with short axis ≥15mm for lymph node based on RECIST 1.1, within 4 weeks&#xD;
             before enrolment;&#xD;
&#xD;
          8. Seven days prior to treatment, haematology test should meet the following requirements&#xD;
             (no treatment with G-CSF or TPO 14 days before test): HGB ≥90 g/L, ANC ≥1.5×109/L, PLT&#xD;
             ≥100×109/L, WBC ≥3.0×109/L bilirubin ≤1.5×ULN, aspartate transaminase (AST)/ alanine&#xD;
             transaminase (ALT) ≤2.5 ×ULN (patients with liver metastasis ≤5xULN), and creatinine&#xD;
             clearance ≥50 mL/min;&#xD;
&#xD;
          9. Peripheral neuropathy (PN) ≤grade 1 on the Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) version 4.03 within 4 weeks before enrolment; patients with any grade&#xD;
             of alopecia are eligible for enrolment;&#xD;
&#xD;
         10. Patients with no major organ dysfunctions and heart disease;&#xD;
&#xD;
         11. Women and men of childbearing potential must agree to take effective contraceptive&#xD;
             measures during the study and within six months after the last treatment. Female&#xD;
             patients must have negative urinary pregnancy test within 7 days before the first&#xD;
             treatmment (postmenopausal women must have no menstruation for at least 12 months&#xD;
             before they are considered unable to conceive);&#xD;
&#xD;
         12. Patients must agree to provide blood samples for specific biomarkers study;&#xD;
&#xD;
         13. No other concurrent investigational agents during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients having history of other malignancies except CRC within the last five years,&#xD;
             but patients with fully recovered in situ cervix carcinoma or non-melanoma skin cancer&#xD;
             are eligible;&#xD;
&#xD;
          2. No other anticancer therapies, such as chemotherapy, hormonal therapy, immunotherapy,&#xD;
             antibody therapy and radiotherapy, or concurrent other chemotherapy during treatment;&#xD;
&#xD;
          3. Patients with uncontrollable brain metastasis, uncontrollable bone metastasis or&#xD;
             recent risk of fracture;&#xD;
&#xD;
          4. Arterial or venous thrombosis or embolic events such as cerebrovascular accident&#xD;
             (including TIA), deep venous thrombosis or pulmonary embolism occurred within one&#xD;
             year;&#xD;
&#xD;
          5. history of symptomatic heart disease (including unstable angina, myocardial infarction&#xD;
             and heart failure);&#xD;
&#xD;
          6. history of interstitial lung disease (ILD), such as interstitial pneumonia, pulmonary&#xD;
             fibrosis, or evidence of ILD on baseline chest CT or MRI;&#xD;
&#xD;
          7. Patients with gastrointestinal bleeding, active gastrointestinal ulcer or&#xD;
             gastrointestinal obstruction (including paralytic intestinal obstruction). Patients&#xD;
             with gastrointestinal perforation or gastrointestinal fistula and abdominal abscess&#xD;
             within 6 month;&#xD;
&#xD;
          8. Previous partial or total gastrectomy, or major operations (such as laparotomy,&#xD;
             thoracotomy and intestinal resection) within 4 weeks；&#xD;
&#xD;
          9. Patients with AEs caused by any previous treatment (including systemic and local&#xD;
             treatment) that have not yet restored to GRADE 1 (excluding hair loss);&#xD;
&#xD;
         10. Patients who are pregnanct (positive pregnancy test), breastfeeding or unwilling to&#xD;
             take contraceptive measures during the trial;&#xD;
&#xD;
         11. active or uncontrollable infections requiring systemic treatment (except simple&#xD;
             urinary or upper respiratory infections) within 2 weeks;&#xD;
&#xD;
         12. Severely allergic to Cremophor or having severe adverse events associated with&#xD;
             paclitaxel in the past;&#xD;
&#xD;
         13. Patients with active pulmonary tuberculosis.Patients having obvious cough blood or&#xD;
             hemoptysis of half a teaspoon (2.5 ml) or more during the last one month;&#xD;
&#xD;
         14. Existence of uncontrolled diabetes, hypertension, active or uncontrollable infections;&#xD;
&#xD;
         15. Patients with serous effusion (such as pleural effusion, pericardial effusion and&#xD;
             ascites) with clinical symptoms requiring intervention or stabilization for less than&#xD;
             4 weeks;&#xD;
&#xD;
         16. Patients with radiology findings that tumors have invaded important perivascular areas&#xD;
             or tumors that are highly likely to invade important blood vessels during treatments&#xD;
             which may lead to fatal massive hemorrhage determined by investigators;&#xD;
&#xD;
         17. Patients with abnormal coagulation function and tendency to bleed;&#xD;
&#xD;
         18. Patients with known HIV infection or untreated active hepatitis B or C;&#xD;
&#xD;
         19. Patients with alcohol or drug addiction, or a history of uncontrollable mental&#xD;
             illness, lack of or limited legal capacity;&#xD;
&#xD;
         20. Patients with other conditions determined by investigators that may affect compliance&#xD;
             with study protocol and study evaluation and are not suitable for participating in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RUIHUA XU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RONGGUO QIU, PhD</last_name>
    <phone>011-86-10-56315388</phone>
    <email>rqiu2001@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LI TANG, PhD</last_name>
    <phone>011-86-10-56315388</phone>
    <email>tangli63b@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RUIHUA XU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YANHONG DENG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YANQIAO ZHANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LIN YANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QIANG YAO, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

